Ruslan A. Zukov

Ruslan A. Zukov

Auto-generated profile, based on publicly available information

Ruslan A. Zukov

V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2024 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
MVMaria I. Volkova
Maria I. Volkova
AKAlexey S. Kalpinskiy
Alexey S. Kalpinskiy
OGOlesya A. Goncharova
Olesya A. Goncharova
KMKonstantin V. Menshikov
Konstantin V. Menshikov
EKElena V. Karabina
Elena V. Karabina
МВМахнутина Мария Валерьевна
Махнутина Мария Валерьевна
Aim To evaluate the safety and toxicity of lenvatinib with pembrolizumab in unselected patients with advanced renal cell carcinoma (RCC). Materials and methods. The Russian phase IV observational study included 151 patients with advanced RCC who received lenvatinib with pembrolizumab in a standard dose regimen in 36 clinical centers of the Russian Federation. Most patients were diagnosed with clear cell RCC (n=145, 96.0%), with synchronous (n=77,51.0%) metastasesof more than one location (n=111,73.5%), removed primary tumor (n=98, 64.9%) and were classified into intermediate and poor IMDC prognostic groups (n=111, 73.5%). Median follow-up was 9.6 (1—68) months. Results. Any adverse events (AEs) were noted in 109 (72.2%), grade ≥3 AEs-in 26 (17.2%), serious AEs-in 9 (6.0%) of 151 patients. There were no deaths caused by AEs. AEs were an indication for lenvatinib dose reduction in 32 (21.2%), a dose interruptions in lenvatinib treatment in 21 (13.9%), and lenvatinib discontinuation in 2 (1.3%) cases. A dose interruptions in pembrolizumab therapy due to AEs was necessary in 15 (9.9%) cases. Both combination drugs were discontinued due to toxicity in 10 (6.6%) cases. AEs were assessed as immune-mediated in 24 (15.9%) patients (grade 3-4 - n=7, 4.6%) and required the prescription of high doses of glucocorticosteroids in 2 (1.3%) patients. Conclusions. A Russian observational study confirmed the acceptable safety profile of lenvatinib plus pembrolizumab therapy in patients with advanced RCC.

5 December 2025 in Journal of Modern Oncology
Verified
Journal Article
Open access
PDF file
MVMaria I. Volkova
Maria I. Volkova
AKAlexey S. Kalpinskiy
Alexey S. Kalpinskiy
OGOlesya A. Goncharova
Olesya A. Goncharova
KMKonstantin V. Menshikov
Konstantin V. Menshikov
OSOlesia A. Stativko
Olesia A. Stativko
МРМухитова Миляуша Расиховна
Мухитова Миляуша Расиховна
Background. A Russian phase IV observational study was initiated to evaluate the efficacy and safety of lenvatinib with pembrolizumab (Len-Pembro) in patients with advanced renal cell carcinoma (RCC) receiving therapy in real-world practice. This article is based on the results of the third analysis conducted with a median follow-up of 23.1 months and reflects data on the efficacy and safety of Len-Pembro in Russian patients. Aim. To evaluate the real-world efficacy and safety of Len-Pembro in patients with advanced RCC with a median follow-up increased to 23.1 months. The primary outcome of the study was progression-free survival (PFS), the secondary outcomes included overall survival (OS), progression-free survival on next-line therapy (PFS2), objective response rate (ORR), duration of response, as well as safety. Materials and methods. The study included data from 165 patients with verified advanced RCC who received Len-Pembro at 36 centers in the Russian Federation from February 05, 2018 to July 30, 2025. The median age was 60 (20–76) years, and 70.3% of the participants were male. Most patients (74.6%) presented with Karnofsky performance score of ≥80%, metachronous metastases (50.9%) of clear cell RCC (93.3%) in 1 organ (75.2%), and had not received any anticancer treatment (91.0%). The IMDC favorable prognosis group included 40 (24.2%), intermediate – 92 (55.8%), and unfavorable prognosis – 33 (20.0%) patients. The median follow-up reached 23.1 (0.5–72.9) months. A total of 110 (66.7%) patients completed Len-Pembro therapy, and 51 (30.9%) patients received next-line treatment. Results. Median PFS reached 25.8 (95% confidence interval – CI 17.0–34.5) months, 23-month PFS – 52.6%; median OS was 39.9 (95% CI 26.9–52.8) months, 23-month OS – 73.1%; median PFS2 was 33.2 (95% CI 23.4–41.1) months, 23-month PFS2 – 66.9%. The ORR was 49.1%, including 3.0% of complete responses, and the disease control rate was 89.1%. The median duration of response reached 29.7 (95% CI 24.9–34.6) months. The incidence of any adverse events (AEs) was 78.8%, severe AEs occurred in 29.1%, fatal AES – in 1.2%, immune-related AEs – 17.0%, severe immune-related AEs – 6.7%. Conclusion. In real-world practice, with increased follow-up duration, the values of PFS, OS, and PFS2 were comparable to those obtained in the registrational study, with a lower ORR and a satisfactory safety profile of the combination of Len-Pembro in advanced RCC.

22 November 2024 in Cancer Urology
Verified
Journal Article
Open access
PDF file
MVM. I. Volkova
M. I. Volkova
AKA. S. Kalpinskiy
A. S. Kalpinskiy
ОGО. A. Goncharova
О. A. Goncharova
КMК. V. Menshikov
К. V. Menshikov
OSO. A. Stativko
O. A. Stativko
ONO. Yu. Novikova
O. Yu. Novikova
Objective: to re-evaluate the efficacy and safety of lenvatinib with pembrolizumab in unselected Russian renal cell carcinoma (RCC) patients, included in the phase IV study, in a median follow-up extended to 17.1 months. The primary end point was progression-free survival (PFS), secondary end points were overall survival (OS), objective response rate (ORR) and duration of response (DOR), disease control rate (DCR) and its duration, as well as safety.Materials and methods. The study included medical data of 165 patients with verified advanced RCC who received lenvatinib with pembrolizumab in 36 centers of the Russian Federation from 05.02.2018 to 25.07.2024. The median age was 60 (20–76) years, the male to female ratio was 2.3:1. The majority of patients had Karnofsky performance status ³80 % (74.6 %), clear cell RCC (93.3 %) without sarcomatoid differentiation (93.3 %), metachronous metastases (50.9 %) localized in 1 organ (75.2 %), were nephrectomized (63.0 %) and did not receive antitumor therapy (91.0 %). At the time of lenvatinib with pembrolizumab therapy start 40 patients (24.2 %) were classified into International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) favorable prognostic group, 92 (55.8 %) in the intermediate prognostic group, and 33 (20.0 %) in the poor prognostic group. The median follow-up was 17.1 (1.5–72.9) months.Results. The median PFS achieved 24.0 (18.7–29.3) months, 17-month PFS 60.5 %. The median OS was 48.9 (18.5– 79.2) months, 17-month OS – 76.1 %. Objective response was registered in 46.0 % of patients including 2.4 % complete responders; the DCR was 92.1 %. The median DOR was 16.6 (2.1–72.9) months, duration of disease control –14.3 (2.1–72.9) months. Confirmed dynamics of change in the sum of tumor foci diameters was recorded in 152 patients, while the median change was –25 % (from –100 % to +29 %). Any decrease in the sum of tumor foci diameters occurred in 69.1 % of cases. The incidence of any adverse events (AE) was 78.2 %, severe AE – 24.2 %, and serious AE – 9.7 %. Immune-mediated AEs developed in 17.0 % of cases and AE grades 3–4 in 6.7 % of cases. Mortality from AEs was 1.2 %.Conclusion. Compared with the registration study, in real-world clinical practice in patients with advanced RCC the lenvatinib with pembrolizumab provides a lower ORR with comparable PFS and OS rates and demonstrates a satisfactory safety profile.

22 January 2025 in Malignant tumours
Verified
Journal Article
Open access
PDF file
Ilya V. TsimafeyeuIlya V. Tsimafeyeu
Ilya V. Tsimafeyeu
OBO. V. Baklanova
O. V. Baklanova
VCViacheslav Chubenko
Viacheslav Chubenko
AKA. S. Kalpinskiy
A. S. Kalpinskiy
SSS. Z. Safina
S. Z. Safina
RZR. A. Zukov
R. A. Zukov
Background: Immunotherapy-based regimens, such as nivolumab plus ipilimumab (Nivo-Ipi) and avelumab plus axitinib (Ave-Axi), are standard first-line treatments for metastatic clear-cell renal cell carcinoma (mRCC) with intermediate or poor IMDC risk. Comparative real-world evidence for these regimens remains limited.Methods: This retrospective cohort study included 102 patients with mRCC treated with Nivo-Ipi (n = 51) or AveAxi (n = 51) from 2018 to 2023. Propensity score matching was used to balance baseline characteristics, including IMDC risk and comorbidities. Primary endpoints were the rate of treatment-related adverse events (TRAEs) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and overall survival (OS).Results: Patient characteristics were balanced across cohorts, with a median age of 63.4 years, 76 % male, and 61 % having chronic cardiovascular diseases. The rate of any grade TRAEs was similar between Nivo-Ipi and Ave-Axi (62.7 % vs. 68.6 %, respectively), as was the rate of grade ≥ 3 TRAEs (11.7 % vs. 17.6 %). Patients treated with Ave-Axi had a significantly extended PFS (15.0 vs 9.7 months; p 0,05). The median OS was not reached.Conclusions: Nivo-Ipi and Ave-Axi are effective and well-tolerated first-line therapies for mRCC in real-world settings. Ave-Axi was associated with a significantly longer PFS and a numerically higher ORR compared to Nivo-Ipi.

4 March 2026 in Malignant tumours
Verified
Journal Article
Open access
PDF file
YGYa. V. Gridneva
Ya. V. Gridneva
MVM. I. Volkova
M. I. Volkova
YAYu. V. Anzhiganova
Yu. V. Anzhiganova
VBV. S. Bragina
V. S. Bragina
ВВВ. А. Водолазский
В. А. Водолазский
Ilya V. TsimafeyeuIlya V. Tsimafeyeu
Ilya V. Tsimafeyeu
Objective: To evaluate the efficacy and safety of avelumab maintenance therapy in patients with metastatic urothelial carcinoma (UC) in real-world practice. Methods: This ambispective study included patients with metastatic UC and measurable tumor lesions, without progression during and after first-line platinum-based chemotherapy (CHT), who received avelumab maintenance therapy (800 mg IV every 2 weeks). The primary endpoint of the study was overall survival (OS). Results: The study included 110 patients, with a predominance of men (81 %). The median age of all patients was 65 (range, 36–84) years. With a median follow-up of 11.9 months, the median OS was not reached; the one-year OS was 78.7 %. The median progression-free survival (PFS) was 9.5 months (95 % CI, 7.8–11.2 months). The objective response rate (ORR) to first-line chemotherapy was 48.2 %. Of the 97 patients with an evaluated objective response, 38 (39.2 %) demonstrated additional objective responses to avelumab therapy (16 complete and 22 partial responses). Grade 3 adverse events during avelumab therapy were observed in 11.8 % of patients. Conclusions: The efficacy and safety of avelumab maintenance therapy in real-world practice are comparable to those in the pivotal study.

30 April 2023 in Voprosy onkologii
Verified
Journal Article
Open access
PDF file
ЮАЮлия Анжиганова
Юлия Анжиганова
ОБОльга Бакланова
Ольга Бакланова
СВСергей Варламов
Сергей Варламов
ВВВладислав Водолазский
Владислав Водолазский
ОЖОльга Жаркова
Ольга Жаркова
ЕУЕвгений Усынин
Евгений Усынин
This article presents the findings of a regional expert council meeting on renal cell carcinoma (RCC) in Siberia and the Far East, held on May 20, 2022, in Novosibirsk. The meeting aimed to coordinate patient management tactics in systemic therapy for advanced RCC (aRCC), discuss clinical experience with immune-targeted regimens, and obtain expert opinions on the study of lenvatinib in combination with pembrolizumab for aRCC patients. The council discussed different approaches to treatment based on clinical guidelines and real world practice, the provision of modern first-line combination therapy options for patients in Siberia and the Far East, and the specific routing of this patient cohort. The agenda included identifying the ideal patient profile for combined immune-targeted therapy with lenvatinib and pembrolizumab, with emphasis on toxicity control. The meeting also addressed significant pharmacoeconomic issues and ways to tackle them. Представлены результаты заседания Регионального Совета экспертов Сибири и Дальнего Востока в нозологии почечно-клеточный рак, состоявшегося 20 мая 2022 г. в Новосибирске с целью согласования тактики ведения пациентов при системной терапии распространенного ПКР (рПКР), обсуждения клинического опыта применения комбинаций иммунотаргетных режимов, получения экспертного мнения относительно результатов исследования применения ленватиниба в комбинации с пембролизумабом у пациентов с рПКР. В задачах Совета было обсуждение различий подходов к лечению на основе клинических рекомендаций и реальной практики, возможностей обеспечения региональных пациентов современными опциями комбинированной терапии 1-й линии, специфики маршрутизации данной когорты больных. Повестка включала поиск портрета пациента, назначение которому комбинированной иммунотаргетной терапии ленватиниба с пембролизумабом окажет максимальный эффект с возможностью контроля токсичности. Одними из существенных оказались вопросы фармакоэкономики и пути их решения.